These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 13212905)

  • 21. [Hormone treatment of prostatic cancer].
    de Voogt HJ
    Ned Tijdschr Geneeskd; 1980 May; 124(22):876-83. PubMed ID: 7383207
    [No Abstract]   [Full Text] [Related]  

  • 22. [Sex-chromatin examinations in cases of prostatic hypertrophy and prostatic carcinoma].
    Baradney G; Mónus Z
    Z Urol Nephrol; 1967 Aug; 60(8):571-5. PubMed ID: 4172042
    [No Abstract]   [Full Text] [Related]  

  • 23. [Significance of the study of calcium metabolism in carcinoma of the breast and prostate before and after various endocrine treatments].
    MOLINATTI GM; CAMANNI F; OLIVETTI M
    Presse Med (1893); 1959 Jan; 67(5):182-5. PubMed ID: 13633839
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prostate carcinoma and testosterone: risks and controversies].
    Rhoden EL; Averbeck MA
    Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):956-62. PubMed ID: 20126847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endometrioid carcinoma of the prostate: a misnomer?
    Vale JA; Patel A; Ball AJ; Hendry WF; Chappell ME; Fisher C
    J R Soc Med; 1992 Jul; 85(7):394-6. PubMed ID: 1629847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.
    Huggins C; Hodges CV
    CA Cancer J Clin; 1972; 22(4):232-40. PubMed ID: 4625049
    [No Abstract]   [Full Text] [Related]  

  • 27. Pathophysiologic and endocrine aspects.
    Sica G
    J Int Med Res; 1990; 18 Suppl 1():8-10. PubMed ID: 2323486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: Testosterone replacement therapy in men with prostate cancer: a time-varying analysis.
    Seftel AD
    J Urol; 2015 Jun; 193(6):1985-6. PubMed ID: 25986797
    [No Abstract]   [Full Text] [Related]  

  • 29. FPIN's clinical inquiries. Testosterone therapy and risk recurrence after treatment of prostate cancer.
    Meza J; Weaver K; Martin S
    Am Fam Physician; 2013 Oct; 88(8):Online. PubMed ID: 24364582
    [No Abstract]   [Full Text] [Related]  

  • 30. Parameter estimation and optimal scheduling algorithm for a mathematical model of intermittent androgen suppression therapy for prostate cancer.
    Guo Q; Lu Z; Hirata Y; Aihara K
    Chaos; 2013 Dec; 23(4):043125. PubMed ID: 24387564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate.
    Habib FK; Lee IR; Stitch SR; Smith PH
    J Endocrinol; 1976 Oct; 71(1):99-107. PubMed ID: 62008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cause-specific survival advantage shown for hormone therapy for diploid prostate tumors.
    Zincke H
    Oncology (Williston Park); 1991 Jul; 5(7):14, 16. PubMed ID: 1837474
    [No Abstract]   [Full Text] [Related]  

  • 33. American Cancer Society Workshop on Combined Castration and Androgen Blockade Therapy in Prostate Cancer. Atlanta, Georgia, September 18-20, 1989. Proceedings.
    Cancer; 1990 Sep; 66(5 Suppl):1007-89. PubMed ID: 2393844
    [No Abstract]   [Full Text] [Related]  

  • 34. The use of coablt 60 teletherapy in the treatment of prostatic carcinoma.
    Dykhuizen RF; Sargent CR; George FW; Kurahara SS
    J Urol; 1968 Sep; 100(3):333-8. PubMed ID: 5677054
    [No Abstract]   [Full Text] [Related]  

  • 35. Autophagy in prostate cancer and androgen suppression therapy.
    Ziparo E; Petrungaro S; Marini ES; Starace D; Conti S; Facchiano A; Filippini A; Giampietri C
    Int J Mol Sci; 2013 Jun; 14(6):12090-106. PubMed ID: 23743823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical course of prostatic carcinoma].
    Hanschke HJ
    Dtsch Med J; 1968 Oct; 19(20):721-5. PubMed ID: 4308210
    [No Abstract]   [Full Text] [Related]  

  • 37. Androgens: risks and benefits.
    Bardin CW; Swerdloff RS; Santen RJ
    J Clin Endocrinol Metab; 1991 Jul; 73(1):4-7. PubMed ID: 1710623
    [No Abstract]   [Full Text] [Related]  

  • 38. Hybrid optimal scheduling for intermittent androgen suppression of prostate cancer.
    Hirata Y; di Bernardo M; Bruchovsky N; Aihara K
    Chaos; 2010 Dec; 20(4):045125. PubMed ID: 21198137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate diseases--role of sex steroids and their inhibitors.
    Welén K; Damber JE
    Best Pract Res Clin Endocrinol Metab; 2011 Apr; 25(2):355-67. PubMed ID: 21397203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Importance of determining steroid hormone receptors and the treatment of prostatic cancer].
    Fedotov IA; Denisov LE; Kozlov VP; Degtiar' VG
    Urol Nefrol (Mosk); 1983; (1):63-70. PubMed ID: 6187115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.